Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600042C
Awardee
Awarding agency
Obligated
$1,499,399

Award facts

Opportunity
  • BAAN44CO6700679 Solicitation number
Contract value 100% obligated
$1,499,398.79 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Newtonville, MA 02458, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00003 -$0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $1,499,399

About this award

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.

Quick answers

Who was awarded contract HHSN261201600042C?

HHSN261201600042C was awarded to Siamab Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600042C worth?

The government has obligated $1,499,399 on HHSN261201600042C.

Was contract HHSN261201600042C competed?

The extent of competition for HHSN261201600042C was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award